Cerevel Therapeutics Holdings Inc CERE shares are buying and selling increased in Wednesday’s after-hours session after AbbVie Inc. ABBV introduced it’ll purchase the corporate for a complete fairness worth of approximately $8.7 billion.
What To Know: The definitive settlement, below which AbbVie will purchase Cerevel Therapeutics, was introduced after the shut of the market on Wednesday. AbbVie will purchase all excellent shares of Cerevel for $45 per share in money, with the transaction anticipated to shut in the course of 2024.
AbbVie chairman and CEO Richard A. Gonzalez famous how the acquisition advantages the corporate’s neuroscience portfolio, saying, “Our present neuroscience portfolio and our mixed pipeline with Cerevel represents a major development alternative nicely into the following decade.”
“AbbVie will leverage its deep business capabilities, worldwide infrastructure, and regulatory and scientific experience to ship substantial shareholder worth with multibillion-dollar gross sales potential throughout Cerevel’s portfolio of belongings.”
Associated Hyperlink: Why MicroAlgo Stock Skyrocketed Today
CERE Worth Motion: Shares of CERE had been up 15.62% at $42.70 within the after-hours session on the time of publication, based on Benzinga Pro.